Content area
Full text
GlaxoSmithKline (GSK) has announced a new partnership with Google's parent company, Alphabet, to carry out research into bioelectronic medicines.
GSK, the United Kingdom's biggest drug company, will form a joint venture with Verily Life Sciences (formerly Google Life Sciences), a division of Alphabet. The joint venture, Galvani Bioelectronics, will focus on the research, development, and commercialisation of bioelectronic medicines. It will be 55% owned by GSK, and Verily will hold the remaining 45%.
The new company's headquarters will be at GSK's global research and development centre in Stevenage, UK. It will also operate a second research hub at Verily's facilities in South San Francisco, USA. The joint venture will combine both companies' intellectual property rights and will...